In a strategic move, Bristol Myers Squibb, a leading pharmaceutical company, has announced the closure of its viral vector production facility in Libertyville, Illinois. This decision is part of a larger consolidation effort to streamline its cell therapy manufacturing operations. The company plans to transfer vector production to its Devens, Massachusetts facility to enhance cost-effectiveness and scalability. A spokesperson from BMS emphasized the importance of internalizing vector production and highlighted significant progress made in this area. The closure aligns with the company’s broader restructuring initiatives aimed at achieving substantial cost savings by 2027. Stay informed about the latest developments in the pharmaceutical manufacturing industry.
Read more about this — here
